A British subsidiary of China’s Sino Biopharmaceutical (HKEX: 1177) has entered into a second licensing deal with Takeda Pharmaceutical (TYO: 4502).
Japan’s largest drugmaker is expanding a collaboration with F-star Therapeutics, a UK and USA-based biotech which was bought by Sino’s UK-based business invoX Pharma in June 2022.
The deal will give Takeda a global license for a novel next-generation antibody, directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab and mAb2 platforms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze